Research on the Whole Process of AI Intelligent Management System for the Diagnosis and Treatment of Inflammatory Bowel Diseases
Observational · No treatment assigned · 1 site · Taichung Veterans General Hospital
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Crohn's Disease (CD) and Ulcerative Colitis (UC). This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 and older
- Any sex
Some of the main requirements, copied from the record:
- Patients diagnosed with IBD (K50.00 to K51.919) within the specified time interval.
- Patients never diagnosed with IBD (K50.00 to K51.919) within the specified time interval.
There are also 2 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 4500 participants are expected to take part.
- Start date: 2026-06-01 (planned).
- Main results expected around 2027-12-01 (estimate from the record).
- 1 study site listed in Taiwan.
Main thing being measured
- developing localized AI models for IBD (No direct participant involvement; retrospective chart review of medical records from 2023 to 2025 only.)
In the researchers’ words
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic immune-mediated disorder requiring long-term management. Clinically, IBD may involve recurrent intestinal inflammation, ulcer formation, and complications such as strictures and fistulas.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Not yet recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis); Crohn's Disease (CD); Ulcerative Colitis (UC); Artificial Intelligence (AI); Natural Language Processing (NLP) |
| Lead sponsor | Taichung Veterans General Hospital |
| Enrollment | 4500 (estimated) |
| Start date | 2026-06-01 |
| Primary completion (est.) | 2027-12-01 |
| First posted | 2026-05-15 |
| Last updated | 2026-05-15 |
| Official title | Research on the Whole Process of AI Intelligent Management System for the Diagnosis and Treatment of Inflammatory Bowel Diseases |
| ClinicalTrials.gov ID | NCT07590271 |
Interventions
- None listed
Full eligibility criteria (from the record)
Inclusion Criteria: Inclusion criteria for the IBD group: Patients diagnosed with IBD (K50.00 to K51.919) within the specified time interval. Inclusion criteria for the non-IBD group: Patients never diagnosed with IBD (K50.00 to K51.919) within the specified time interval. Exclusion Criteria: Patients not within the specified time interval Deceased patients Exclusion criteria for the non-IBD group: Patients not within the specified time interval Deceased patients Patients with fewer than 5 hospital visits
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Taichung Veterans General Hospital | Taichung, Xitun Dist. | Taiwan |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.